{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T19:59:55Z","timestamp":1779134395240,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007333","name":"Alzheimer's Disease Neuroimaging Initiative","doi-asserted-by":"crossref","award":["U01 AG024904"],"award-info":[{"award-number":["U01 AG024904"]}],"id":[{"id":"10.13039\/100007333","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001316","name":"Abbott","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AstraZeneca AB"},{"name":"Bayer Schering Pharma AG,"},{"name":"Bristol-Myers Squibb"},{"name":"Eisai Global Clinical Development"},{"DOI":"10.13039\/501100003037","name":"Elan Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003037","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006775","name":"GE Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006775","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Glaxo-SmithKline"},{"DOI":"10.13039\/501100005061","name":"Innogenetics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005061","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Eli Lilly and Co"},{"name":"Medpace Inc"},{"name":"Merck and Co Inc"},{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pfizer Inc"},{"DOI":"10.13039\/100007013","name":"F. Hoffman-La Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007110","name":"Schering-Plough","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007110","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Synarc Inc"},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH","award":["P30 AG010129"],"award-info":[{"award-number":["P30 AG010129"]}]},{"name":"NIH","award":["K01 AG030514"],"award-info":[{"award-number":["K01 AG030514"]}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Goteborgs Lakaresallskap"},{"name":"Svenska Lakaresallskapet"},{"DOI":"10.13039\/501100005754","name":"Sahlgrenska Universitetssjukhuset","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005754","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008226","name":"Carl-Bertil Laurells fond","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008226","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Klinisk Biokemi i Norden"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.neurobiolaging.2013.08.027","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T18:15:55Z","timestamp":1380651355000},"page":"614-622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults"],"prefix":"10.1016","volume":"35","author":[{"given":"Niklas","family":"Mattsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Insel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Nosheny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Q.","family":"Trojanowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie M.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duygu","family":"Tosun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JAD-2006-9309","article-title":"Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders","volume":"9","author":"Abdi","year":"2006","journal-title":"J.\u00a0Alzheimers Dis"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N.\u00a0Engl. J. Med"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nature Rev. Neurol"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib5","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","article-title":"Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years","volume":"70","author":"Braak","year":"2011","journal-title":"J.\u00a0Neuropathol. Exp. Neurol"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib7","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/brain\/awl269","article-title":"CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease","volume":"129","author":"Buerger","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrneurol.2013.21","article-title":"Alzheimer disease: A\u03b2-independent processes\u2014rethinking preclinical AD","volume":"9","author":"Ch\u00e9telat","year":"2013","journal-title":"Nature Rev. Neurol"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1212\/WNL.0b013e318246d67a","article-title":"Accelerated cortical atrophy in cognitively normal elderly with high \u03b2-amyloid deposition","volume":"78","author":"Ch\u00e9telat","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib10","doi-asserted-by":"crossref","first-page":"e18850","DOI":"10.1371\/journal.pone.0018850","article-title":"Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis","volume":"6","author":"Craig-Schapiro","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in\u00a0vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2217\/bmm.12.42","article-title":"Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease","volume":"6","author":"Fagan","year":"2012","journal-title":"Biomark. Med"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0006-8993(97)00958-X","article-title":"Hepatocyte growth factor (HGF\/SF) in Alzheimer's disease","volume":"779","author":"Fenton","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0896-6273(02)00569-X","article-title":"Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain","volume":"33","author":"Fischl","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/cercor\/bhg087","article-title":"Automatically parcellating the human cerebral cortex","volume":"14","author":"Fischl","year":"2004","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib16","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/cercor\/bhp279","article-title":"Brain atrophy in healthy aging is related to CSF levels of A{beta}1-42","volume":"20","author":"Fjell","year":"2010","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neulet.2009.03.038","article-title":"Apolipoprotein D modulates F2-isoprostane and 7-ketocholesterol formation and has a neuroprotective effect on organotypic hippocampal cultures after kainate-induced excitotoxic injury","volume":"455","author":"He","year":"2009","journal-title":"Neurosci. Lett"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1212\/WNL.0b013e3181b879ac","article-title":"Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease","volume":"73","author":"Henneman","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00401-010-0667-0","article-title":"Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment","volume":"119","author":"Hu","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib20","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1212\/WNL.0b013e318266fa70","article-title":"Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease","volume":"79","author":"Hu","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jmri.21049","article-title":"The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods","volume":"27","author":"Jack","year":"2008","journal-title":"J.\u00a0Magn. Reson. Imaging"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.imlet.2007.09.002","article-title":"Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression","volume":"114","author":"Motta","year":"2007","journal-title":"Immunol. Lett"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib24","first-page":"995","article-title":"Apolipoprotein D expression absence in degenerating neurons of human central nervous system","volume":"23","author":"Navarro","year":"2008","journal-title":"Histol. Histopathol"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib25","article-title":"Association of gray matter atrophy with age, \u03b2-amyloid, and cognition in aging","author":"Oh","year":"2013","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000323417","article-title":"Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease","volume":"1","author":"Ohrfelt","year":"2011","journal-title":"Dement. Geriatr. Cogn. Dis. Extra"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1373\/clinchem.2004.039347","article-title":"Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology","volume":"51","author":"Olsson","year":"2005","journal-title":"Clin. Chem"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib28","doi-asserted-by":"crossref","first-page":"14946","DOI":"10.1523\/JNEUROSCI.4305-10.2010","article-title":"Amyloid-independent mechanisms in Alzheimer's disease pathogenesis","volume":"30","author":"Pimplikar","year":"2010","journal-title":"J.\u00a0Neurosci"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib29","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.neuroimage.2012.02.084","article-title":"Within-subject template estimation for unbiased longitudinal image analysis","volume":"61","author":"Reuter","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib30","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1148\/radiol.2293021299","article-title":"Regional brain atrophy rate predicts future cognitive decline: 6-Year longitudinal MR imaging study of normal aging","volume":"229","author":"Rusinek","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib31","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa0806142","article-title":"Age, neuropathology, and dementia","volume":"360","author":"Savva","year":"2009","journal-title":"N.\u00a0Engl. J. Med"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ana.22315","article-title":"Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid A\u03b21-42","volume":"68","author":"Schott","year":"2010","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.neurobiolaging.2008.06.016","article-title":"Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study","volume":"31","author":"Sluimer","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib35","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1046\/j.1471-4159.1998.71041643.x","article-title":"Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients","volume":"71","author":"Terrisse","year":"1998","journal-title":"J.\u00a0Neurochem"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib36","doi-asserted-by":"crossref","first-page":"e28527","DOI":"10.1371\/journal.pone.0028527","article-title":"Plasma biomarkers of brain atrophy in Alzheimer's disease","volume":"6","author":"Thambisetty","year":"2011","journal-title":"PLoS One"},{"issue":"suppl 3","key":"10.1016\/j.neurobiolaging.2013.08.027_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3233\/JAD-2011-0006","article-title":"Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data","volume":"26","author":"Tosun","year":"2011","journal-title":"J.\u00a0Alzheimer Dis"},{"key":"10.1016\/j.neurobiolaging.2013.08.027_bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jalz.2010.08.230","article-title":"Transforming CSF A?42 measures into calculated Pittsburgh Compound B (PIBcalc) units of brain A? amyloid","volume":"7","author":"Weigand","year":"2011","journal-title":"Alzheimers Dement"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458013003722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458013003722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:21:44Z","timestamp":1759317704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458013003722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0197458013003722"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.08.027","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}